Satlin, A.
441  results:
Search for persons X
?
1

P.468 Cardiometabolic safety of lumateperone (ITI-007): pos..:

Satlin, A. ; Durgam, S. ; Vanover, K.E....
European Neuropsychopharmacology.  40 (2020)  - p. S265-S266 , 2020
 
?
2

P.446 Efficacy and safety of lumateperone (ITI-007) in the ..:

Durgam, S. ; Satlin, A. ; Vanover, K.E....
European Neuropsychopharmacology.  40 (2020)  - p. S253-S254 , 2020
 
?
3

P.673 Results from a 12-month open-label safety study of lu..:

Correll, C.U. ; Vanover, K.E. ; Durgam, S....
European Neuropsychopharmacology.  29 (2019)  - p. S455-S456 , 2019
 
?
4

P.671 Efficacy and safety of lumateperone tosylate 42mg in ..:

Kane, J.M. ; Vanover, K.E. ; Durgam, S....
European Neuropsychopharmacology.  29 (2019)  - p. S453-S454 , 2019
 
?
5

Development of perampanel in epilepsy:

Satlin, A. ; Kramer, L. D. ; Laurenza, A.
Acta Neurologica Scandinavica.  127 (2013)  - p. 3-8 , 2013
 
?
 
?
 
?
 
?
11

Aliskiren, an Orally Effective Renin Inhibitor, Provides An..:

POOL, J ; SCHMIEDER, R ; AZIZI, M...
American Journal of Hypertension.  20 (2007)  1 - p. 11-20 , 2007
 
?
12

Aliskiren, a Novel Renin Inhibitor, Has Greater Blood Press..:

Santonastaso, M ; Uresin, Y ; Taylor, A...
High Blood Pressure & Cardiovascular Prevention.  14 (2007)  3 - p. 145-196 , 2007
 
1-15